# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 21, "Diabetes Obes Metab .", "", "<http://ctro/data#Publication_75549> <http://ctro/data#hasJournal> \"Diabetes Obes Metab .\"."
1, PublicationYear, 22, 26, "2018", "", "<http://ctro/data#Publication_75549> <http://ctro/data#hasPublicationYear> \"2018\"."
8, Title, 106, 284, "Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin : The GetGoal - L - C randomized trial .", "", "<http://ctro/data#Publication_75549> <http://ctro/data#hasTitle> \"Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin : The GetGoal - L - C randomized trial .\"."
99938, Lixisenatide, 129, 141, "lixisenatide", "", 
140, Ethnicity, 145, 177, "a predominantly Asian population", "", "<http://ctro/data#Ethnicity_75574> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Ethnicity>. <http://ctro/data#Population_75572> <http://ctro/data#hasEthnicity> <http://ctro/data#Ethnicity_75574>."
3, Ethnicity, 161, 166, "Asian", "", 
4, Type2Diabetes, 183, 198, "type 2 diabetes", "", "<http://ctro/data#ClinicalTrial_75556> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
6, Precondition, 199, 243, "insufficiently controlled with basal insulin", "", "<http://ctro/data#Population_75572> <http://ctro/data#hasPrecondition> \"insufficiently controlled with basal insulin\"."
5, Insulin, 230, 243, "basal insulin", "", 
146, Insulin, 236, 243, "insulin", "", 
7, Randomized, 266, 276, "randomized", "", "<http://ctro/data#ClinicalTrial_75556> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
9, Author, 285, 291, "Yang W", "", "<http://ctro/data#Publication_75549> <http://ctro/data#hasAuthor> \"Yang W\"."
10, Author, 300, 305, "Min K", "", "<http://ctro/data#Publication_75549> <http://ctro/data#hasAuthor> \"Min K\"."
11, Author, 314, 320, "Zhou Z", "", "<http://ctro/data#Publication_75549> <http://ctro/data#hasAuthor> \"Zhou Z\"."
12, Author, 329, 333, "Li L", "", "<http://ctro/data#Publication_75549> <http://ctro/data#hasAuthor> \"Li L\"."
13, Author, 342, 346, "Xu X", "", "<http://ctro/data#Publication_75549> <http://ctro/data#hasAuthor> \"Xu X\"."
14, Author, 355, 360, "Zhu D", "", "<http://ctro/data#Publication_75549> <http://ctro/data#hasAuthor> \"Zhu D\"."
15, Author, 369, 387, "Venkateshwar Rao A", "", "<http://ctro/data#Publication_75549> <http://ctro/data#hasAuthor> \"Venkateshwar Rao A\"."
16, Author, 396, 405, "Murthy LS", "", "<http://ctro/data#Publication_75549> <http://ctro/data#hasAuthor> \"Murthy LS\"."
17, Author, 414, 421, "Zhang N", "", "<http://ctro/data#Publication_75549> <http://ctro/data#hasAuthor> \"Zhang N\"."
18, Author, 430, 434, "Li I", "", "<http://ctro/data#Publication_75549> <http://ctro/data#hasAuthor> \"Li I\"."
19, Author, 443, 455, "Niemoeller E", "", "<http://ctro/data#Publication_75549> <http://ctro/data#hasAuthor> \"Niemoeller E\"."
20, Author, 465, 472, "Shang S", "", "<http://ctro/data#Publication_75549> <http://ctro/data#hasAuthor> \"Shang S\"."
21, China, 508, 513, "China", "", "<http://ctro/data#Population_75572> <http://ctro/data#hasCountry> <http://ctro/data#China>."
29, Japan, 516, 521, "Japan", "", "<http://ctro/data#Population_75572> <http://ctro/data#hasCountry> <http://ctro/data#Japan>."
22, China, 554, 559, "China", "", "<http://ctro/data#Population_75572> <http://ctro/data#hasCountry> <http://ctro/data#China>."
30, SouthKorea, 601, 612, "South Korea", "", "<http://ctro/data#Population_75572> <http://ctro/data#hasCountry> <http://ctro/data#SouthKorea>."
23, China, 690, 695, "China", "", 
24, China, 726, 731, "China", "", 
25, China, 764, 769, "China", "", 
26, China, 813, 818, "China", "", 
27, China, 862, 867, "China", "", 
31, India, 907, 912, "India", "", "<http://ctro/data#Population_75572> <http://ctro/data#hasCountry> <http://ctro/data#India>."
32, India, 958, 963, "India", "", 
28, China, 992, 997, "China", "", 
33, Germany, 1048, 1055, "Germany", "", "<http://ctro/data#Population_75572> <http://ctro/data#hasCountry> <http://ctro/data#Germany>."
44, ObjectiveDescription, 1065, 1319, "To assess the effects on glycaemic control of lixisenatide vs placebo as add - on treatment to basal insulin ( BI )  ±  metformin and effects on glycated haemoglobin ( HbA1c ) reduction in patients with insufficiently controlled type 2 diabetes ( T2D ) .", "", "<http://ctro/data#ClinicalTrial_75556> <http://ctro/data#hasObjectiveDescription> \"To assess the effects on glycaemic control of lixisenatide vs placebo as add - on treatment to basal insulin ( BI )  ±  metformin and effects on glycated haemoglobin ( HbA1c ) reduction in patients with insufficiently controlled type 2 diabetes ( T2D ) .\"."
99930, Lixisenatide, 1111, 1123, "lixisenatide", "", 
35, Placebo, 1127, 1134, "placebo", "", 
36, Insulin, 1160, 1173, "basal insulin", "", 
37, Insulin, 1176, 1178, "BI", "", 
38, Metformin, 1185, 1194, "metformin", "", 
39, HbA1c, 1210, 1230, "glycated haemoglobin", "", 
40, HbA1c, 1233, 1238, "HbA1c", "", 
189, Precondition, 1254, 1317, "patients with insufficiently controlled type 2 diabetes ( T2D )", "", 
41, Type2Diabetes, 1294, 1309, "type 2 diabetes", "", 
42, Type2Diabetes, 1312, 1315, "T2D", "", 
45, NumberPatientsCT, 1347, 1350, "448", "", "<http://ctro/data#ClinicalTrial_75556> <http://ctro/data#hasNumberPatientsCT> \"448\"."
47, Precondition, 1358, 1381, "inadequately controlled", "", 
46, Type2Diabetes, 1382, 1385, "T2D", "", 
48, Randomized, 1391, 1401, "randomized", "", 
194, AllocationRatio, 1404, 1409, "1 : 1", "", "<http://ctro/data#AllocationRatio_75560> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#AllocationRatio>. <http://ctro/data#ClinicalTrial_75556> <http://ctro/data#hasAllocationRatio> <http://ctro/data#AllocationRatio_75560>."
99932, Lixisenatide, 1415, 1427, "lixisenatide", "", "<http://ctro/data#Medication_75622> <http://ctro/data#hasDrug> <http://ctro/data#Lixisenatide>."
50, Placebo, 1431, 1438, "placebo", "", "<http://ctro/data#Medication_75629> <http://ctro/data#hasDrug> <http://ctro/data#Placebo>."
51, Insulin, 1454, 1456, "BI", "", 
52, Metformin, 1461, 1470, "metformin", "", 
53, Duration, 1475, 1485, "24   weeks", "", "<http://ctro/data#ClinicalTrial_75556> <http://ctro/data#hasCTduration> \"24   weeks\"."
54, Duration, 1495, 1503, "8 - week", "", 
55, Insulin, 1534, 1536, "BI", "", 
56, DoseDescription, 1541, 1629, "titrated to a target self - monitored plasma glucose ( SMPG ; 4 . 4 - 5 . 6   mmol / L )", "", 
196, PlasmaGlucose, 1555, 1593, "target self - monitored plasma glucose", "", 
99940, PlasmaGlucose, 1596, 1600, "SMPG", "", 
58, Millimoles_per_litre, 1619, 1627, "mmol / L", "", 
59, HbA1c, 1676, 1681, "HbA1c", "", 
60, TimePoint, 1687, 1695, "baseline", "", 
61, TimePoint, 1699, 1706, "week 24", "", 
63, PostprandialPlasmaGlucose, 1787, 1823, "2 - hour postprandial plasma glucose", "", 
64, PostprandialPlasmaGlucose, 1826, 1829, "PPG", "", 
205, EndPointDescription, 1834, 1848, "7 - point SMPG", "", 
65, BodyWeight, 1869, 1880, "body weight", "", 
66, BodyWeight, 1883, 1885, "BW", "", 
208, InsulinDose, 1902, 1909, "BI dose", "", 
70, FastingPlasmaGlucose, 1912, 1934, "fasting plasma glucose", "", 
210, EndPointDescription, 1941, 1959, "safety assessments", "", 
71, TimePoint, 1972, 1980, "Baseline", "", 
72, Insulin, 2043, 2050, "insulin", "", 
99933, Lixisenatide, 2082, 2094, "lixisenatide", "", 
74, Placebo, 2111, 2118, "placebo", "", 
75, Mean, 2122, 2126, "mean", "", "<http://ctro/data#Mean_75668> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_75666> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_75668>."
62, TimePoint, 2139, 2147, "baseline", "", 
84, BaseLineValue, 2150, 2155, "7 . 9", "", "<http://ctro/data#Outcome_75671> <http://ctro/data#hasBaselineValue> \"7 . 9\"."
76, Percentage, 2156, 2157, "%", "", "<http://ctro/data#Endpoint_75666> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
86, SdDevBL, 2193, 2199, "0 . 66", "", "<http://ctro/data#Outcome_75671> <http://ctro/data#hasSdDevBL> \"0 . 66\"."
85, BaseLineValue, 2206, 2211, "7 . 9", "", "<http://ctro/data#Outcome_75698> <http://ctro/data#hasBaselineValue> \"7 . 9\"."
77, Percentage, 2212, 2213, "%", "", 
87, SdDevBL, 2216, 2222, "0 . 70", "", "<http://ctro/data#Outcome_75698> <http://ctro/data#hasSdDevBL> \"0 . 70\"."
88, TimePoint, 2245, 2252, "week 24", "", "<http://ctro/data#Outcome_75671> <http://ctro/data#hasTimePoint> \"week 24\". <http://ctro/data#Outcome_75698> <http://ctro/data#hasTimePoint> \"week 24\"."
89, HbA1c, 2256, 2261, "HbA1c", "", "<http://ctro/data#Endpoint_75666> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
90, LeastSquaresMean, 2264, 2282, "least squares mean", "", 
219, Reduction, 2323, 2329, "0 . 62", "", "<http://ctro/data#Outcome_75671> <http://ctro/data#hasChangeValue> \"0 . 62\"."
78, Percentage, 2330, 2331, "%", "", 
93, SdErrorChangeValue, 2334, 2340, "0 . 09", "", "<http://ctro/data#Outcome_75671> <http://ctro/data#hasSdErrorChangeValue> \"0 . 09\"."
220, Reduction, 2348, 2354, "0 . 11", "", "<http://ctro/data#Outcome_75698> <http://ctro/data#hasChangeValue> \"0 . 11\"."
79, Percentage, 2355, 2356, "%", "", 
94, SdErrorChangeValue, 2359, 2365, "0 . 09", "", "<http://ctro/data#Outcome_75698> <http://ctro/data#hasSdErrorChangeValue> \"0 . 09\"."
95, PvalueDiff, 2370, 2381, "P  < . 0001", "", "<http://ctro/data#DiffBetweenGroups_75725> <http://ctro/data#hasPvalueDiff> \"P  < . 0001\"."
99939, HbA1c, 2443, 2448, "HbA1c", "", 
97, PostprandialPlasmaGlucose, 2459, 2473, "Two - hour PPG", "", "<http://ctro/data#Endpoint_75734> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#PostprandialPlasmaGlucose>."
99941, Mean, 2482, 2486, "mean", "", "<http://ctro/data#Mean_75741> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_75739> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_75741>."
100, PlasmaGlucose, 2487, 2491, "SMPG", "", "<http://ctro/data#PlasmaGlucose_75740> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#PlasmaGlucose>. <http://ctro/data#Endpoint_75739> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#PlasmaGlucose_75740>."
99, Mean, 2496, 2500, "mean", "", "<http://ctro/data#Mean_75746> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_75744> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_75746>."
101, BodyWeight, 2501, 2503, "BW", "", "<http://ctro/data#Endpoint_75744> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#BodyWeight>."
232, ObservedResult, 2504, 2524, "were reduced further", "", "<http://ctro/data#Outcome_75754> <http://ctro/data#hasObservedResult> \"were reduced further\". <http://ctro/data#Outcome_75781> <http://ctro/data#hasObservedResult> \"were reduced further\". <http://ctro/data#Outcome_75808> <http://ctro/data#hasObservedResult> \"were reduced further\"."
231, InsulinDose, 2535, 2542, "BI dose", "", "<http://ctro/data#InsulinDose_75750> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#InsulinDose>. <http://ctro/data#Endpoint_75749> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#InsulinDose_75750>."
233, ObservedResult, 2543, 2552, "was lower", "", "<http://ctro/data#Outcome_75862> <http://ctro/data#hasObservedResult> \"was lower\"."
99934, Lixisenatide, 2558, 2570, "lixisenatide", "", 
104, Placebo, 2576, 2583, "placebo", "", 
234, Reduction, 2588, 2594, "1 . 12", "", "<http://ctro/data#Outcome_75808> <http://ctro/data#hasChangeValue> \"1 . 12\"."
109, Kg, 2597, 2599, "kg", "", "<http://ctro/data#Endpoint_75744> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Kg>."
239, Increment, 2603, 2609, "0 . 04", "", "<http://ctro/data#Outcome_75835> <http://ctro/data#hasChangeValue> \"0 . 04\"."
110, Kg, 2612, 2614, "kg", "", 
113, PvalueDiff, 2617, 2628, "P  < . 0001", "", "<http://ctro/data#DiffBetweenGroups_75916> <http://ctro/data#hasPvalueDiff> \"P  < . 0001\"."
235, Reduction, 2635, 2640, "3 . 0", "", "<http://ctro/data#Outcome_75862> <http://ctro/data#hasChangeValue> \"3 . 0\"."
111, Int_Unit, 2643, 2644, "U", "", "<http://ctro/data#Endpoint_75749> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Int_Unit>."
236, Reduction, 2650, 2655, "1 . 9", "", "<http://ctro/data#Outcome_75889> <http://ctro/data#hasChangeValue> \"1 . 9\"."
112, Int_Unit, 2658, 2659, "U", "", 
114, PvalueDiff, 2662, 2673, "P  = . 0033", "", "<http://ctro/data#DiffBetweenGroups_75925> <http://ctro/data#hasPvalueDiff> \"P  = . 0033\"."
244, EndPointDescription, 2716, 2730, "adverse events", "", "<http://ctro/data#EndPointDescription_75989> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_75988> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_75989>."
99935, Lixisenatide, 2749, 2761, "lixisenatide", "", 
116, Placebo, 2767, 2774, "placebo", "", 
117, PercentageAffected, 2777, 2783, "63 . 8", "", "<http://ctro/data#Outcome_75934> <http://ctro/data#hasPercentageAffected> \"63 . 8\"."
118, PercentageAffected, 2789, 2795, "40 . 8", "", "<http://ctro/data#Outcome_75961> <http://ctro/data#hasPercentageAffected> \"40 . 8\"."
119, SymptomaticHypoglycemia, 2834, 2859, "symptomatic hypoglycaemia", "", "<http://ctro/data#Endpoint_75993> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#SymptomaticHypoglycemia>."
99936, Lixisenatide, 2874, 2886, "lixisenatide", "", 
120, PercentageAffected, 2887, 2893, "15 . 6", "", "<http://ctro/data#Outcome_75998> <http://ctro/data#hasPercentageAffected> \"15 . 6\"."
123, Placebo, 2899, 2906, "placebo", "", 
121, PercentageAffected, 2907, 2913, "13 . 5", "", "<http://ctro/data#Outcome_76025> <http://ctro/data#hasPercentageAffected> \"13 . 5\"."
251, ConclusionComment, 2934, 3154, "In Asian patients insufficiently controlled on BI  ±  metformin , lixisenatide was superior to placebo in glycaemic control , with a tolerability profile in line with other glucagon - like peptide - 1 receptor agonists .", "", "<http://ctro/data#ClinicalTrial_75556> <http://ctro/data#hasConclusionComment> \"In Asian patients insufficiently controlled on BI  ±  metformin , lixisenatide was superior to placebo in glycaemic control , with a tolerability profile in line with other glucagon - like peptide - 1 receptor agonists .\"."
124, Ethnicity, 2937, 2942, "Asian", "", 
106276, Precondition, 2943, 2997, "patients insufficiently controlled on BI  ±  metformin", "", "<http://ctro/data#Population_75572> <http://ctro/data#hasPrecondition> \"patients insufficiently controlled on BI  ±  metformin\"."
125, Insulin, 2981, 2983, "BI", "", 
126, Metformin, 2988, 2997, "metformin", "", 
99937, Lixisenatide, 3000, 3012, "lixisenatide", "", 
128, Placebo, 3029, 3036, "placebo", "", 
129, PMID, 3366, 3374, "28742225", "", "<http://ctro/data#Publication_75549> <http://ctro/data#hasPMID> \"28742225\"."
